Business
Microbix Schedules Release of Results for Q2 Fiscal 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTC...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix Schedules Release of Results for Q2 Fiscal 2025Results Release and Webinar Discussion on Morning of May 15, 2025\n\n\n\n MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (\n \n TSX: MBX, OTCQX: MBXBF, Microbix®\n \n ), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“\n \n Q2 2025\n \n ”) prior to the start of trading on May 15, 2025. At 11:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q2 2025 results with its CEO, CFO, and COO.\n \n\n Investor and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering at:\n \n https://us02web.zoom.us/webinar/register/WN_WAJTH6BvQSiYKoh6wf2eaA\n \n .\n \n\n It will also be live-streamed to YouTube at:\n \n https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw\n \n .\n \n\n Telephone participation in the webinar can be arranged by contacting Microbix or Adelaide Capital at the contact numbers provided at the end of this news release.\n \n\n A replay of the webinar will also be made available on Adelaide Capital’s YouTube channel.\n \n\n\n About Microbix Biosystems Inc.\n \n\n Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues now targeting C$ 2.0 million per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE ma...